Objective To assess the clinical efficacy and safety of Shuxuetong in the treatment of cerebral infarction. Methods Randomized controlled trials (RCTs) were identified from MEDLINE (1996 to Feb. 2006), EMBASE (1984 to Dec. 2005), Cochrane Controlled Trials Register (Issue 4, 2005), Chinese Cochrane Centre Database, CBMdisc (1978 to Dec. 2005). We handsearched the related published and unpublished data and their references. All trials about Shuxuetong injection for cerebral infarction were included. Data were extracted and evaluated by two reviewers independently with designed extraction form. RevMan 4.2.8 software was used for data analysis. Results Eleven RCTs involving 1 122 patients were included. The results of meta-analysis were listed as follows: ① Total effective rate: Compared with Danshen, three studies showed that Shuxuetong were more effective with OR 4.01, 95%CI 2.00 to 8.04; ② Adverse effect: The number of adverse drug reaction was small and the symptoms were moderate; ③ Neurologic impairment score: Compared with safflower, one study showed that Shuxuetong had better improvement with WMD -2.60, 95%CI -3.23 to -1.97. Conclusions Shuxuetong may increase the total effective rate of cerebral infarction. More high quality trials are required.
目的:觀察采用疏血通注射液聯合ACEI/ARB治療早期糖尿病腎病(DN)的療效。方法:將78例2型DN患者隨機分為對照組(ACEI/ARB)和治療組(ACEI/ARB+疏血通注射液),療程4周。比較兩組治療前和治療后尿微量白蛋白(mAlb),Scr、BUN等指標的變化。結果:(1)治療后治療組和對照組尿白蛋白均顯著下降(Plt;0.01,Plt;0.05),治療組比對照組下降更為明顯(Plt;0.05)。(2)治療后兩組血漿白蛋白均增加(Plt;0.01),治療組與對照組治療后比較無明顯差異(Pgt;0.05)。(3)治療后兩組Scr、BUN、TC、TG和血鉀均無明顯變化。結論:聯合應用疏血通注射液能有效減少早期DN患者的蛋白尿,改善腎功能。